Lonza to Add New Revenue Driver with Vaxcyte's Pneumonia Shot
Dow Jones
Oct 06
0629 GMT - News that Vaxcyte's experimental pneumonia vaccine held up against two approved shots in a late-stage clinical trial should open a new revenue stream for Switzerland's Lonza Group starting in a couple of years, RBC Capital Markets' Charles Weston says in a research note. "Lonza is fully embedded in Vaxcyte's manufacturing supply chain through multiple overlapping agreements," the analyst says. Vaxcyte's vaccine is projected to reach $4 billion in annual peak sales, though it is unlikely to launch before 2028, RBC says. At its peak, this could translate into $400 million to $550 million in revenue for Lonza, the analyst estimates.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.